Amicus Therapeutics (NASDAQ: FOLD) reported Q1 EPS of ($0.18), $0.04 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $86.3 million versus the consensus estimate of $83.07 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.